{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:17:49Z","timestamp":1788153469108,"version":"build-2803163510"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Hidradenitis suppurativa (HS) is an extremely painful skin condition with both nociceptive and neuropathic components. Biologics may offer superior neuropathic pain relief and impede worsening of this disease compared to other treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Of the three currently FDA-approved biologics (adalimumab, bimekizumab, and secukinumab), bimekizumab shows the largest absolute reduction in skin pain and the earliest onset of pain improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review explores the pathophysiology and causes of neuropathic pain development in HS, highlights current FDA-approved and emerging biologics for its management, and raises awareness of neuropathic pain in HS. Clinical trial data assessing pain are unstandardized, and further elucidation of pain outcomes using standardized assessments of\u00a0neuropathic pain is crucial for determining whether biologics targeting mediators that drive neuropathic pain development are effective in treating this aspect of HS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11916-026-01551-y","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:26:01Z","timestamp":1788150361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuropathic Pain Management Using Novel Biologics in Moderate-to-Severe Hidradenitis Suppurativa"],"prefix":"10.1007","volume":"30","author":[{"given":"Josephine M.","family":"Feeney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikayla A.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanisha M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Ardoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I.","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Abd-Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"1551_CR1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjd.19556","volume":"183","author":"K Wolk","year":"2020","unstructured":"Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2020;183:999\u20131010. https:\/\/doi.org\/10.1111\/bjd.19556.","journal-title":"Br J Dermatol"},{"key":"1551_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jdv.16677","volume":"35","author":"TV Nguyen","year":"2021","unstructured":"Nguyen TV, Damiani G, Orenstein LaV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol JEADV. 2021;35:50\u201361. https:\/\/doi.org\/10.1111\/jdv.16677.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1551_CR3","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.jid.2025.12.025","volume":"146","author":"BL Peacker","year":"2026","unstructured":"Peacker BL, Ly L, Hwang JC, Gravel-Pucillo K, Zheng C, Wheless LE, et al. Multiomics analyses prioritize disease genes and pathways in hidradenitis suppurativa. J Invest Dermatol. 2026;146:1807\u2013e18152. https:\/\/doi.org\/10.1016\/j.jid.2025.12.025.","journal-title":"J Invest Dermatol"},{"key":"1551_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-med-051223-031234","volume":"76","author":"S McCarthy","year":"2025","unstructured":"McCarthy S. Hidradenitis Suppurativa. Annu Rev Med. 2025;76:69\u201380. https:\/\/doi.org\/10.1146\/annurev-med-051223-031234.","journal-title":"Annu Rev Med"},{"key":"1551_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.det.2024.12.001","volume":"43","author":"S Look-Why","year":"2025","unstructured":"Look-Why S, Kirimlishvili S, Porter M, Kimball A. Hidradenitis Suppurativa Epidemiology - ClinicalKey. Dermatol Clin. 2025;43:145\u201354.","journal-title":"Dermatol Clin"},{"key":"1551_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jaad.2024.09.013","volume":"91","author":"B Midgette","year":"2024","unstructured":"Midgette B, Garg A. Epidemiology of hidradenitis suppurativa and its comorbid conditions. J Am Acad Dermatol. 2024;91:S3\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.013.","journal-title":"J Am Acad Dermatol"},{"key":"1551_CR7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/ddg.14796","volume":"20","author":"A Tsentemeidou","year":"2022","unstructured":"Tsentemeidou A, Sotiriou E, Ioannides D, Vakirlis E. Hidradenitis suppurativa-related expenditure, a call for awareness: systematic review of literature. JDDG J Dtsch Dermatol Ges. 2022;20:1061\u201372. https:\/\/doi.org\/10.1111\/ddg.14796.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"1551_CR8","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.2017.16691","volume":"318","author":"DML Saunte","year":"2017","unstructured":"Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017;318:2019\u201332. https:\/\/doi.org\/10.1001\/jama.2017.16691.","journal-title":"JAMA"},{"key":"1551_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092311","volume":"11","author":"R Shukla","year":"2022","unstructured":"Shukla R, Karagaiah P, Patil A, Farnbach K, Ortega-Loayza AG, Tzellos T, et al. Surgical treatment in hidradenitis suppurativa. J Clin Med. 2022;11:2311. https:\/\/doi.org\/10.3390\/jcm11092311.","journal-title":"J Clin Med"},{"key":"1551_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1403455","volume":"11","author":"P Mendes-Bastos","year":"2024","unstructured":"Mendes-Bastos P, Benhadou F, Venturini M, Molina-Levya A, Thomas N, Alarcon I, et al. Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review. Front Med. 2024;11:1403455. https:\/\/doi.org\/10.3389\/fmed.2024.1403455.","journal-title":"Front Med"},{"key":"1551_CR11","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s13555-025-01487-y","volume":"15","author":"A Garg","year":"2025","unstructured":"Garg A, Hsiao J, Porter ML, Shi V. Current treatments and future directions for hidradenitis suppurativa: a narrative review of completed and ongoing phase 3 clinical trials of biologic therapies. Dermatol Ther. 2025;15:2361\u201377. https:\/\/doi.org\/10.1007\/s13555-025-01487-y.","journal-title":"Dermatol Ther"},{"key":"1551_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jamadermatol.2025.1976","volume":"161","author":"A Garg","year":"2025","unstructured":"Garg A, Cohn E, Midgette B, Frasier K, Strunk A. Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa: A Living Systematic Review and Network Meta-Analysis. JAMA Dermatol. 2025;161:931\u201340. https:\/\/doi.org\/10.1001\/jamadermatol.2025.1976.","journal-title":"JAMA Dermatol"},{"key":"1551_CR13","doi-asserted-by":"publisher","first-page":"1760206","DOI":"10.3389\/fimmu.2026.1760206","volume":"17","author":"SX Chen","year":"2026","unstructured":"Chen SX, Wafae BG, de O, Look-Why S, Otto T, Snyder C, Sweet W, et al. Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational study. Front Immunol. 2026;17:1760206. https:\/\/doi.org\/10.3389\/fimmu.2026.1760206.","journal-title":"Front Immunol"},{"key":"1551_CR14","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.3390\/cimb45050280","volume":"45","author":"MJ Diaz","year":"2023","unstructured":"Diaz MJ, Aflatooni S, Abdi P, Li R, Anthony MR, Neelam S, et al. Hidradenitis suppurativa: molecular etiology, pathophysiology, and management\u2014a systematic review. Curr Issues Mol Biol. 2023;45:4400\u201315. https:\/\/doi.org\/10.3390\/cimb45050280.","journal-title":"Curr Issues Mol Biol"},{"key":"1551_CR15","doi-asserted-by":"publisher","first-page":"adv00364","DOI":"10.2340\/00015555-3724","volume":"101","author":"PK Krajewski","year":"2021","unstructured":"Krajewski PK, Matusiak \u0141, von Stebut E, Schultheis M, Kirschner U, Nikolakis G, et al. Pain in Hidradenitis Suppurativa: A Cross-sectional Study of 1,795 Patients. Acta Derm Venereol. 2021;101:adv00364. https:\/\/doi.org\/10.2340\/00015555-3724.","journal-title":"Acta Derm Venereol"},{"key":"1551_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/bjd.17935","volume":"182","author":"RM Nielsen","year":"2020","unstructured":"Nielsen RM, Linds\u00f8 Andersen P, Sigsgaard V, Theut Riis P, Jemec GB. Pain perception in patients with hidradenitis suppurativa. Br J Dermatol. 2020;182:166\u201374. https:\/\/doi.org\/10.1111\/bjd.17935.","journal-title":"Br J Dermatol"},{"key":"1551_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9124046","volume":"9","author":"S Garcovich","year":"2020","unstructured":"Garcovich S, Muratori S, Moltrasio C, Buscemi AA, Giovanardi G, Malvaso D, et al. Prevalence of neuropathic pain and related characteristics in hidradenitis suppurativa: a cross-sectional study. J Clin Med. 2020;9:4046. https:\/\/doi.org\/10.3390\/jcm9124046.","journal-title":"J Clin Med"},{"key":"1551_CR18","volume-title":"StatPearls","author":"S Kendroud","year":"2026","unstructured":"Kendroud S, Fitzgerald LA, Murray IV, Hanna A. Physiology, Nociceptive Pathways. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"1551_CR19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, et al. Hidradenitis suppurativa. Lancet. 2025;405:420\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(24)02475-9.","journal-title":"Lancet"},{"key":"1551_CR20","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1172\/JCI45178","volume":"120","author":"CJ Woolf","year":"2010","unstructured":"Woolf CJ. What is this thing called pain? J Clin Invest. 2010;120:3742\u20134. https:\/\/doi.org\/10.1172\/JCI45178.","journal-title":"J Clin Invest"},{"key":"1551_CR21","first-page":"S256","volume":"12","author":"B Nicholson","year":"2006","unstructured":"Nicholson B. Differential diagnosis: nociceptive and neuropathic pain. Am J Manag Care. 2006;12:S256\u2013262.","journal-title":"Am J Manag Care"},{"key":"1551_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/jamadermatol.2023.3243","volume":"159","author":"A Alsouhibani","year":"2023","unstructured":"Alsouhibani A, Speck P, Cole EF, Mustin DE, Li Y, Barron JR, et al. Quantitative sensory testing to characterize sensory changes in hidradenitis suppurativa skin lesions. JAMA Dermatol. 2023;159:1102\u201311. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3243.","journal-title":"JAMA Dermatol"},{"key":"1551_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1530-7085.2003.03034.x","volume":"3","author":"CT Hartrick","year":"2003","unstructured":"Hartrick CT, Kovan JP, Shapiro S. The numeric rating scale for clinical pain measurement: a ratio measure? Pain Pract. 2003;3:310\u20136. https:\/\/doi.org\/10.1111\/j.1530-7085.2003.03034.x.","journal-title":"Pain Pract"},{"key":"1551_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000536268","volume":"10","author":"J Melchor","year":"2024","unstructured":"Melchor J, Prajapati S, Pichardo RO, Feldman SR. Cytokine-mediated molecular pathophysiology of hidradenitis suppurativa: a narrative review. Skin Appendage Disord. 2024;10:172\u20139. https:\/\/doi.org\/10.1159\/000536268.","journal-title":"Skin Appendage Disord"},{"key":"1551_CR25","doi-asserted-by":"publisher","first-page":"14062","DOI":"10.1523\/JNEUROSCI.3795-08.2008","volume":"28","author":"AM Binshtok","year":"2008","unstructured":"Binshtok AM, Wang H, Zimmermann K, Amaya F, Vardeh D, Shi L, et al. Nociceptors Are Interleukin-1\u03b2 Sensors. J Neurosci. 2008;28:14062\u201373. https:\/\/doi.org\/10.1523\/JNEUROSCI.3795-08.2008.","journal-title":"J Neurosci"},{"key":"1551_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15104","volume":"33","author":"J Tang","year":"2024","unstructured":"Tang J, Zhao S, Shi H, Li X, Ran L, Cao J, et al. Effects on peripheral and central nervous system of key inflammatory intercellular signalling peptides and proteins in psoriasis. Exp Dermatol. 2024;33:e15104. https:\/\/doi.org\/10.1111\/exd.15104.","journal-title":"Exp Dermatol"},{"key":"1551_CR27","doi-asserted-by":"publisher","unstructured":"Lowe MM, Naik HB, Clancy S, Pauli M, Smith KM, Bi Y, et al. Immunopathogenesis of hidradenitis suppurativa and response to anti\u2013TNF-\u03b1 therapy. JCI Insight. 2022;5. https:\/\/doi.org\/10.1172\/jci.insight.139932.","DOI":"10.1172\/jci.insight.139932"},{"key":"1551_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/life15050785","volume":"15","author":"M Garc\u00eda-Dom\u00ednguez","year":"2025","unstructured":"Garc\u00eda-Dom\u00ednguez M. The role of TNF-\u03b1 in neuropathic pain: an immunotherapeutic perspective. Life. 2025;15:785. https:\/\/doi.org\/10.3390\/life15050785.","journal-title":"Life"},{"key":"1551_CR29","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s13311-022-01278-9","volume":"19","author":"RE Sorge","year":"2022","unstructured":"Sorge RE, Si Y, Norian LA, Guha A, Moore GE, Nabors LB, et al. Inhibition of the RNA Regulator HuR by SRI-42127 Attenuates Neuropathic Pain After Nerve Injury Through Suppression of Neuroinflammatory Responses. Neurotherapeutics. 2022;19:1649\u201361. https:\/\/doi.org\/10.1007\/s13311-022-01278-9.","journal-title":"Neurotherapeutics"},{"key":"1551_CR30","doi-asserted-by":"publisher","first-page":"R473","DOI":"10.1152\/ajpregu.00355.2012","volume":"304","author":"D Salvemini","year":"2013","unstructured":"Salvemini D, Kim SF, Mollace V. Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications. Am J Physiol - Regul Integr Comp Physiol. 2013;304:R473\u201387. https:\/\/doi.org\/10.1152\/ajpregu.00355.2012.","journal-title":"Am J Physiol - Regul Integr Comp Physiol"},{"key":"1551_CR31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/bjd\/ljae442","volume":"192","author":"J Rastrick","year":"2025","unstructured":"Rastrick J, Edwards H, Ferecsk\u00f3 AS, Le Friec G, Manghera A, Page M, et al. The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples. Br J Dermatol. 2025;192:660\u201371. https:\/\/doi.org\/10.1093\/bjd\/ljae442.","journal-title":"Br J Dermatol"},{"key":"1551_CR32","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","volume":"139","author":"E Witte-H\u00e4ndel","year":"2019","unstructured":"Witte-H\u00e4ndel E, Wolk K, Tsaousi A, Irmer ML, M\u00f6\u00dfner R, Shomroni O, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol. 2019;139:1294\u2013305. https:\/\/doi.org\/10.1016\/j.jid.2018.11.018.","journal-title":"J Invest Dermatol"},{"key":"1551_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2021.2918","volume":"157","author":"P Aarts","year":"2021","unstructured":"Aarts P, Aitken JJ, van Straalen KR. Prevalence of Central Sensitization in Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2021;157:1\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2918.","journal-title":"JAMA Dermatol"},{"key":"1551_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","volume":"81","author":"P Aarts","year":"2021","unstructured":"Aarts P, Dudink K, Vossen ARJV, van Straalen KR, Ardon CB, Prens EP, et al. Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa. Drugs. 2021;81:1397\u2013410. https:\/\/doi.org\/10.1007\/s40265-021-01566-2.","journal-title":"Drugs"},{"key":"1551_CR35","unstructured":"41 - Quantitative Sensory Testing. and Skin Biopsies Suggest Pain in Hidradenitis Suppurativa may be both Inflammatory and Neuropathic - Google Search n.d. https:\/\/www.jpain.org\/article\/S1526-5900(25)00915-0\/fulltext (accessed July 8, 2026)."},{"key":"1551_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaad.2021.06.843","volume":"86","author":"S Wright","year":"2022","unstructured":"Wright S, Strunk A, Garg A. Prevalence of depression among children, adolescents, and adults with hidradenitis suppurativa. J Am Acad Dermatol. 2022;86:55\u201360. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.843.","journal-title":"J Am Acad Dermatol"},{"key":"1551_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bjd\/ljac018","volume":"188","author":"LAV Orenstein","year":"2023","unstructured":"Orenstein LAV, Salame N, Siira MR, Urbanski M, Flowers NI, Echuri H, et al. Pain Experiences among those Living with Hidradenitis Suppurativa: A Qualitative Study. Br J Dermatol. 2023;188:41\u201351. https:\/\/doi.org\/10.1093\/bjd\/ljac018.","journal-title":"Br J Dermatol"},{"key":"1551_CR38","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1185\/030079906X132488","volume":"22","author":"R Freynhagen","year":"2006","unstructured":"Freynhagen R, Baron R, Gockel U, T\u00f6lle TR. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911\u201320. https:\/\/doi.org\/10.1185\/030079906X132488.","journal-title":"Curr Med Res Opin"},{"key":"1551_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000533262","volume":"240","author":"PJ Speck","year":"2024","unstructured":"Speck PJ, Alsouhibani A, Mustin DE, Cole EF, Harper DE, Orenstein LAV. Correlation between PainDETECT Questionnaire and quantitative sensory testing for the detection of neuropathic pain in hidradenitis suppurativa. Dermatology. 2024;240:152\u20135. https:\/\/doi.org\/10.1159\/000533262.","journal-title":"Dermatology"},{"key":"1551_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.pain.2006.01.041","volume":"123","author":"R Rolke","year":"2006","unstructured":"Rolke R, Baron R, Maier C, T\u00f6lle TR, Treede -DR, Beyer A, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006;123:231\u201343. https:\/\/doi.org\/10.1016\/j.pain.2006.01.041.","journal-title":"Pain"},{"key":"1551_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2020.09.039","volume":"85","author":"KT Savage","year":"2021","unstructured":"Savage KT, Singh V, Patel ZS, Yannuzzi CA, McKenzie-Brown AM, Lowes MA, et al. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. J Am Acad Dermatol. 2021;85:187\u201399. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.039.","journal-title":"J Am Acad Dermatol"},{"key":"1551_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00482-015-0093-2","volume":"35","author":"M M\u00fccke","year":"2021","unstructured":"M\u00fccke M, Cuhls H, Radbruch L, Baron R, Maier C, T\u00f6lle T, et al. Quantitative sensory testing (QST). Engl version Schmerz. 2021;35:153\u201360. https:\/\/doi.org\/10.1007\/s00482-015-0093-2.","journal-title":"Engl version Schmerz"},{"key":"1551_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"Ay Finlay","year":"1994","unstructured":"Finlay Ay, Khan Gk. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"1551_CR44","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","volume":"60","author":"A Alikhan","year":"2009","unstructured":"Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: A comprehensive review. J Am Acad Dermatol. 2009;60:539\u201361. https:\/\/doi.org\/10.1016\/j.jaad.2008.11.911.","journal-title":"J Am Acad Dermatol"},{"key":"1551_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81:76\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.067.","journal-title":"J Am Acad Dermatol"},{"key":"1551_CR46","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamasurg.2020.2611","volume":"155","author":"J Hamad","year":"2020","unstructured":"Hamad J, McCormick BJ, Sayed CJ, Paci K, Overton M, Daubert T, et al. Multidisciplinary Update on Genital Hidradenitis Suppurativa: A Review. JAMA Surg. 2020;155:970. https:\/\/doi.org\/10.1001\/jamasurg.2020.2611.","journal-title":"JAMA Surg"},{"key":"1551_CR47","doi-asserted-by":"publisher","DOI":"10.5070\/D31911020616","volume":"19","author":"N Scheinfeld","year":"2013","unstructured":"Scheinfeld N. Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine. Dermatol Online J. 2013;19:20616.","journal-title":"Dermatol Online J"},{"key":"1551_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2049463712438493","volume":"6","author":"H Pathan","year":"2012","unstructured":"Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6:11\u20136. https:\/\/doi.org\/10.1177\/2049463712438493.","journal-title":"Br J Pain"},{"key":"1551_CR49","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","volume":"24","author":"N Soliman","year":"2025","unstructured":"Soliman N, Moisset X, Ferraro MC, de Andrade DC, Baron R, Belton J, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025;24:413\u201328. https:\/\/doi.org\/10.1016\/S1474-4422(25)00068-7.","journal-title":"Lancet Neurol"},{"key":"1551_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40122-017-0091-4","volume":"6","author":"D Fornasari","year":"2017","unstructured":"Fornasari D. Pharmacotherapy for Neuropathic Pain: A Review. Pain Ther. 2017;6:25\u201333. https:\/\/doi.org\/10.1007\/s40122-017-0091-4.","journal-title":"Pain Ther"},{"key":"1551_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.neuroscience.2020.12.021","volume":"455","author":"S-Y Yoon","year":"2021","unstructured":"Yoon S-Y, Roh D-H, Yeo J-H, Woo J, Han SH, Kim K-S. Analgesic efficacy of \u03b12 adrenergic receptor agonists depends on the chronic state of neuropathic pain: role of regulator of G protein signaling 4. Neuroscience. 2021;455:177\u201394. https:\/\/doi.org\/10.1016\/j.neuroscience.2020.12.021.","journal-title":"Neuroscience"},{"key":"1551_CR52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11916-026-01506-3","volume":"30","author":"JM Feeney","year":"2026","unstructured":"Feeney JM, Noble RK, Bautista TB, Patel M, Abd-Elsayed A, Ahmadzadeh S, et al. Clinical Efficacy and Risks of Clonidine Infusion for Sedation and Analgesia: A Narrative Review. Curr Pain Headache Rep. 2026;30:70. https:\/\/doi.org\/10.1007\/s11916-026-01506-3.","journal-title":"Curr Pain Headache Rep"},{"key":"1551_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/medsci14010144","volume":"14","author":"JM Feeney","year":"2026","unstructured":"Feeney JM, Duet SJ, Jones CB, Baffi AJ, Rayes Elmalakh S, Bembenick KN, et al. Safety and efficacy of dexmedetomidine as an adjuvant in epidural anesthesia for labor analgesia: a narrative review. Med Sci. 2026;14:144. https:\/\/doi.org\/10.3390\/medsci14010144.","journal-title":"Med Sci"},{"key":"1551_CR54","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40122-022-00361-5","volume":"11","author":"M Rekatsina","year":"2022","unstructured":"Rekatsina M, Theodosopoulou P, Staikou C. Perioperative dexmedetomidine or lidocaine infusion for the prevention of chronic postoperative and neuropathic pain after gynecological surgery: a randomized, placebo-controlled, double-blind study. Pain Ther. 2022;11:529\u201343. https:\/\/doi.org\/10.1007\/s40122-022-00361-5.","journal-title":"Pain Ther"},{"key":"1551_CR55","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0304-3959(94)00209-W","volume":"61","author":"JC Eisenach","year":"1995","unstructured":"Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D, Epidural Clonidine Study Group, et al. Epidural clonidine analgesia for intractable cancer pain. Pain. 1995;61:391\u20139. https:\/\/doi.org\/10.1016\/0304-3959(94)00209-W.","journal-title":"Pain"},{"key":"1551_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21070844","volume":"21","author":"V Fattori","year":"2016","unstructured":"Fattori V, Hohmann MSN, Rossaneis AC, Pinho-Ribeiro FA, Verri WA. Capsaicin: current understanding of its mechanisms and therapy of pain and other pre-clinical and clinical uses. Molecules. 2016;21:844. https:\/\/doi.org\/10.3390\/molecules21070844.","journal-title":"Molecules"},{"key":"1551_CR57","doi-asserted-by":"publisher","first-page":"281","DOI":"10.12788\/cutis.0383","volume":"108","author":"GM Jeha","year":"2021","unstructured":"Jeha GM, Kodumudi V, O\u2019Quinn MC, Luckett KO, Dickerson TG, Kaye RJ, et al. Management of Acute and Chronic Pain Associated With Hidradenitis Suppurativa: A Comprehensive Review of Pharmacologic and Therapeutic Considerations in Clinical Practice. Cutis. 2021;108:281\u20136. https:\/\/doi.org\/10.12788\/cutis.0383.","journal-title":"Cutis"},{"key":"1551_CR58","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bjd\/ljad345","volume":"190","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Frew J, Jemec GBE, Kimball AB, Kirby B, Bechara FG, et al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol. 2024;190:149\u201362. https:\/\/doi.org\/10.1093\/bjd\/ljad345.","journal-title":"Br J Dermatol"},{"key":"1551_CR59","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375:422\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504370.","journal-title":"N Engl J Med"},{"key":"1551_CR60","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.3390\/biomedicines10102522","volume":"10","author":"M Burlando","year":"2022","unstructured":"Burlando M, Fabbrocini G, Marasca C, Dapavo P, Chiricozzi A, Malvaso D, et al. Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study. Biomedicines. 2022;10:2522. https:\/\/doi.org\/10.3390\/biomedicines10102522.","journal-title":"Biomedicines"},{"key":"1551_CR61","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s13555-023-00906-2","volume":"13","author":"P Fernandez-Crehuet","year":"2023","unstructured":"Fernandez-Crehuet P, Haselgruber S, Padial-Gomez A, Vasquez-Chinchay F, Fernandez-Ballesteros MD, L\u00f3pez-Riquelme I, et al. Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study. Dermatol Ther. 2023;13:1029\u201338. https:\/\/doi.org\/10.1007\/s13555-023-00906-2.","journal-title":"Dermatol Ther"},{"key":"1551_CR62","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401:747\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(23)00022-3.","journal-title":"Lancet"},{"key":"1551_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CCID.S449367","volume":"17","author":"F Martora","year":"2024","unstructured":"Martora F, Marasca C, Cacciapuoti S, Fariello F, Potestio L, Battista T, et al. Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52-week real-life study. Clin Cosmet Investig Dermatol. 2024;17:159\u201366. https:\/\/doi.org\/10.2147\/CCID.S449367.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1551_CR64","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403:2504\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(24)00101-6.","journal-title":"Lancet"},{"key":"1551_CR65","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.2147\/CCID.S565686","volume":"18","author":"F Martora","year":"2025","unstructured":"Martora F, Megna M. Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published Literature. Clin Cosmet Investig Dermatol. 2025;18:3511\u20139. https:\/\/doi.org\/10.2147\/CCID.S565686.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1551_CR66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","volume":"90","author":"JS Kirby","year":"2024","unstructured":"Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2024;90:521\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.034.","journal-title":"J Am Acad Dermatol"},{"key":"1551_CR67","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jaad.2024.12.046","volume":"92","author":"LS Ackerman","year":"2025","unstructured":"Ackerman LS, Schlosser BJ, Zhan T, Prajapati VH, Fretzin S, Takahashi H, et al. Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study. J Am Acad Dermatol. 2025;92:1252\u201360. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.046.","journal-title":"J Am Acad Dermatol"},{"key":"1551_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2026.138667","volume":"883","author":"S McGaraughty","year":"2026","unstructured":"McGaraughty S, Strasburg D, McCarthy R, Ciura S, Kouzehgarani GN, Wilper T, et al. Jak1 inhibition reduces acute allodynia induced by specific upstream cytokines in rats: implications for the onset of Jak1 pain modulation. Neurosci Lett. 2026;883:138667. https:\/\/doi.org\/10.1016\/j.neulet.2026.138667.","journal-title":"Neurosci Lett"},{"key":"1551_CR69","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","volume":"397","author":"KA Papp","year":"2021","unstructured":"Papp KA, Weinberg MA, Morris A, Reich K. IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397:1564\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(21)00440-2.","journal-title":"Lancet"},{"key":"1551_CR70","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/13543784.2025.2500292","volume":"34","author":"S Dogra","year":"2025","unstructured":"Dogra S, Singh S. Assessing the clinical progress of the bispecific nanobody sonelokimab. Expert Opin Investig Drugs. 2025;34:253\u20138. https:\/\/doi.org\/10.1080\/13543784.2025.2500292.","journal-title":"Expert Opin Investig Drugs"},{"key":"1551_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1705553","volume":"16","author":"L Qiu","year":"2025","unstructured":"Qiu L, Hu F, Tao X. Research progress on the application of nanobodies in immunity and infectious skin diseases. Front Immunol. 2025;16:1705553. https:\/\/doi.org\/10.3389\/fimmu.2025.1705553.","journal-title":"Front Immunol"},{"key":"1551_CR72","doi-asserted-by":"publisher","first-page":"114726","DOI":"10.1016\/j.addr.2023.114726","volume":"195","author":"YJ Kim","year":"2023","unstructured":"Kim YJ, Sang J, Xiang Z, Shen Y, Shi Z, Nanobodies Y. Robust miniprotein binders in biomedicine. Adv Drug Deliv Rev. 2023;195:114726. https:\/\/doi.org\/10.1016\/j.addr.2023.114726.","journal-title":"Adv Drug Deliv Rev"},{"key":"1551_CR73","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/bjd\/ljae144","volume":"191","author":"A Alavi","year":"2024","unstructured":"Alavi A, Prens EP, Kimball AB, Frew JW, Krueger JG, Mukhopadhyay S, et al. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial. Br J Dermatol. 2024;191:508\u201318. https:\/\/doi.org\/10.1093\/bjd\/ljae144.","journal-title":"Br J Dermatol"},{"key":"1551_CR74","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000688","volume":"3","author":"JD Goldstein","year":"2020","unstructured":"Goldstein JD, Bassoy EY, Caruso A, Palomo J, Rodriguez E, Lemeille S, et al. IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis. Life Sci Alliance. 2020;3:e202000688. https:\/\/doi.org\/10.26508\/lsa.202000688.","journal-title":"Life Sci Alliance"},{"key":"1551_CR75","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19895488","volume":"11","author":"CA Constantinou","year":"2019","unstructured":"Constantinou CA, Fragoulis GE, Nikiphorou E. Hidradenitis suppurativa: infection, autoimmunity, or both? Ther Adv Musculoskelet Dis. 2019;11:1759720X19895488. https:\/\/doi.org\/10.1177\/1759720X19895488.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1551_CR76","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/glia.23552","volume":"67","author":"Q Li","year":"2019","unstructured":"Li Q, Liu S, Li L, Ji X, Wang M, Zhou J. Spinal IL-36\u03b3\/IL-36R participates in the maintenance of chronic inflammatory pain through astroglial JNK pathway. Glia. 2019;67:438\u201351. https:\/\/doi.org\/10.1002\/glia.23552.","journal-title":"Glia"},{"key":"1551_CR77","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jamadermatol.2026.0155","volume":"162","author":"AB Kimball","year":"2026","unstructured":"Kimball AB, Sawicki KT, Ackerman L, Lima H, Giamarellos-Bourboulis EJ, Zhan T, et al. Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure. JAMA Dermatol. 2026;162:469\u201377. https:\/\/doi.org\/10.1001\/jamadermatol.2026.0155.","journal-title":"JAMA Dermatol"},{"key":"1551_CR78","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamadermatol.2023.4800","volume":"160","author":"H Ben Abdallah","year":"2024","unstructured":"Ben Abdallah H, Bregnh\u00f8j A, Emmanuel T, Ghatnekar G, Johansen C, Iversen L. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial. JAMA Dermatol. 2024;160:63\u201370. https:\/\/doi.org\/10.1001\/jamadermatol.2023.4800.","journal-title":"JAMA Dermatol"},{"key":"1551_CR79","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/bjd.20880","volume":"186","author":"A Bregnh\u00f8j","year":"2022","unstructured":"Bregnh\u00f8j A, Thuesen KKH, Emmanuel T, Litman T, Grek CL, Ghatnekar GS, et al. HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study. Br J Dermatol. 2022;186:861\u201374. https:\/\/doi.org\/10.1111\/bjd.20880.","journal-title":"Br J Dermatol"},{"key":"1551_CR80","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/hep.24802","volume":"55","author":"A Ambade","year":"2012","unstructured":"Ambade A, Catalano D, Lim A, Mandrekar P. Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in mice. Hepatology. 2012;55:1585\u201395. https:\/\/doi.org\/10.1002\/hep.24802.","journal-title":"Hepatology"},{"key":"1551_CR81","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1.","journal-title":"Signal Transduct Target Ther"},{"key":"1551_CR82","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1016\/j.jemermed.2024.01.007","volume":"66","author":"M Shalaby","year":"2024","unstructured":"Shalaby M, Sahni R, Puebla D, Fernandez S. Modified PECS II Block for Axillary Hidradenitis Suppurativa. J Emerg Med. 2024;66:e701\u20133. https:\/\/doi.org\/10.1016\/j.jemermed.2024.01.007.","journal-title":"J Emerg Med"},{"key":"1551_CR83","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejogrb.2021.11.429","volume":"268","author":"Y Shahabuddin","year":"2022","unstructured":"Shahabuddin Y, Gleeson N, Maguire PJ. Surgeon-administered ilio-inguinal and pudendal nerve blocks for major vulval surgery: An observational study with visual analogue pain scoring. Eur J Obstet Gynecol Reprod Biol. 2022;268:87\u201391. https:\/\/doi.org\/10.1016\/j.ejogrb.2021.11.429.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1551_CR84","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.bpa.2019.07.013","volume":"33","author":"I Urits","year":"2019","unstructured":"Urits I, Ostling PS, Novitch MB, Burns JC, Charipova K, Gress KL, et al. Truncal regional nerve blocks in clinical anesthesia practice. Best Pract Res Clin Anaesthesiol. 2019;33:559\u201371. https:\/\/doi.org\/10.1016\/j.bpa.2019.07.013.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"1551_CR85","doi-asserted-by":"publisher","unstructured":"Eldabe S, Nevitt S, Hunter CW, Rosenow JM, Maden M, Goudman L, et al. Systematic review and network meta-analysis of randomized trial evidence of spinal cord stimulation for chronic pain. Reg Anesth Pain Med. 2026:rapm-2025-107068. https:\/\/doi.org\/10.1136\/rapm-2025-107068.","DOI":"10.1136\/rapm-2025-107068"},{"key":"1551_CR86","doi-asserted-by":"publisher","unstructured":"O\u2019Connell NE, Ferraro MC, Gibson W, Rice AS, Vase L, Coyle D, et al. Implanted spinal neuromodulation interventions for chronic pain in adults. Cochrane Database Syst Rev. 2021;2022. https:\/\/doi.org\/10.1002\/14651858.CD013756.pub2.","DOI":"10.1002\/14651858.CD013756.pub2"},{"key":"1551_CR87","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/S0140-6736(21)00794-7","volume":"397","author":"H Knotkova","year":"2021","unstructured":"Knotkova H, Hamani C, Sivanesan E, Le Beuffe MFE, Moon JY, Cohen SP, et al. Neuromodulation for chronic pain. Lancet. 2021;397:2111\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00794-7.","journal-title":"Lancet"},{"key":"1551_CR88","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2147\/JPR.S364370","volume":"16","author":"KB Chapman","year":"2023","unstructured":"Chapman KB, Sayed D, Lamer T, Hunter C, Weisbein J, Patel KV, et al. Best practices for dorsal root ganglion stimulation for chronic pain: guidelines from the American Society of Pain and Neuroscience. J Pain Res. 2023;16:839\u201379. https:\/\/doi.org\/10.2147\/JPR.S364370.","journal-title":"J Pain Res"},{"key":"1551_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011890.pub3","author":"W Gibson","year":"2019","unstructured":"Gibson W, Wand BM, Meads C, Catley MJ, O\u2019Connell NE. Transcutaneous electrical nerve stimulation (TENS) for chronic pain - an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2019. https:\/\/doi.org\/10.1002\/14651858.CD011890.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1551_CR90","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra2110098","volume":"389","author":"TJ Smith","year":"2023","unstructured":"Smith TJ, Wang EJ, Loprinzi CL. Cutaneous electroanalgesia for relief of chronic and neuropathic pain. N Engl J Med. 2023;389:158\u201364. https:\/\/doi.org\/10.1056\/NEJMra2110098.","journal-title":"N Engl J Med"},{"key":"1551_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-051073","volume":"12","author":"MI Johnson","year":"2022","unstructured":"Johnson MI, Paley CA, Jones G, Mulvey MR, Wittkopf PG. Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS study). BMJ Open. 2022;12:e051073. https:\/\/doi.org\/10.1136\/bmjopen-2021-051073.","journal-title":"BMJ Open"},{"key":"1551_CR92","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/ijd.16428","volume":"62","author":"C Ulschmid","year":"2023","unstructured":"Ulschmid C, Serrano L, Wu R, Roth GM, Sokumbi O. African American race is a risk factor for severe hidradenitis suppurativa. Int J Dermatol. 2023;62:657\u201363. https:\/\/doi.org\/10.1111\/ijd.16428.","journal-title":"Int J Dermatol"},{"key":"1551_CR93","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/jvc2.409","volume":"3","author":"MT Polaskey","year":"2024","unstructured":"Polaskey MT, Chovatiya R. Understanding disparities in hidradenitis suppurativa through social and structural determinants of health. JEADV Clinical Practice. 2024;3:945\u201361. https:\/\/doi.org\/10.1002\/jvc2.409.","journal-title":"JEADV Clinical Practice"},{"key":"1551_CR94","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000550402","volume":"242","author":"LA Barnes","year":"2026","unstructured":"Barnes LA, Rinderknecht F-AB, Orenstein LAV, Naik HB. Global Pain Management Trends and Barriers to Care in Hidradenitis Suppurativa. Dermatology. 2026;242:252\u201363. https:\/\/doi.org\/10.1159\/000550402.","journal-title":"Dermatology"},{"key":"1551_CR95","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamadermatol.2025.5112","volume":"162","author":"Y Hernandez","year":"2026","unstructured":"Hernandez Y, Gonzalez N, Ghanshani R, Castillo Valladares HB, Amerson EH, Naik HB, et al. Health System Experiences and Care Engagement in Latine Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2026;162:151. https:\/\/doi.org\/10.1001\/jamadermatol.2025.5112.","journal-title":"JAMA Dermatol"},{"key":"1551_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0331032","volume":"20","author":"AK Gupta","year":"2025","unstructured":"Gupta AK, Economopoulos V, Mirmirani P, Magalhaes R. Understanding the evolving treatment landscape of hidradenitis suppurativa: an analysis of All of Us. PLoS One. 2025;20:e0331032. https:\/\/doi.org\/10.1371\/journal.pone.0331032.","journal-title":"PLoS One"},{"key":"1551_CR97","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1056\/NEJMsa2034159","volume":"385","author":"NE Morden","year":"2021","unstructured":"Morden NE, Chyn D, Wood A, Meara E. Racial Inequality in Prescription Opioid Receipt \u2014 Role of Individual Health Systems. N Engl J Med. 2021;385:342\u201351. https:\/\/doi.org\/10.1056\/NEJMsa2034159.","journal-title":"N Engl J Med"},{"key":"1551_CR98","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2018.02.053","volume":"79","author":"A Garg","year":"2018","unstructured":"Garg A, Papagermanos V, Midura M, Strunk A, Merson J. Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: A population-based analysis in the United States. J Am Acad Dermatol. 2018;79:495\u2013e5001. https:\/\/doi.org\/10.1016\/j.jaad.2018.02.053.","journal-title":"J Am Acad Dermatol"},{"key":"1551_CR99","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamadermatol.2022.4610","volume":"158","author":"CX Wang","year":"2022","unstructured":"Wang CX, Buss JL, Keller M, Anadkat MJ. Factors Associated With Dermatologic Follow-up vs Emergency Department Return in Patients With Hidradenitis Suppurativa After an Initial Emergency Department Visit. JAMA Dermatol. 2022;158:1378. https:\/\/doi.org\/10.1001\/jamadermatol.2022.4610.","journal-title":"JAMA Dermatol"},{"key":"1551_CR100","doi-asserted-by":"publisher","first-page":"518","DOI":"10.5114\/ada.2021.112075","volume":"40","author":"K Lipa","year":"2023","unstructured":"Lipa K, Zaj\u0105c N, Witkowski G, Ciechanowicz P, Wiszniewski K, Szyma\u0144ska E, et al. Hidradenitis suppurativa - biologic therapy and other available treatment options. Postepy Dermatol Alergol. 2023;40:518\u201328. https:\/\/doi.org\/10.5114\/ada.2021.112075.","journal-title":"Postepy Dermatol Alergol"},{"key":"1551_CR101","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1523\/JNEUROSCI.3858-05.2006","volume":"26","author":"X Jin","year":"2006","unstructured":"Jin X, Gereau RW. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J Neurosci Off J Soc Neurosci. 2006;26:246\u201355. https:\/\/doi.org\/10.1523\/JNEUROSCI.3858-05.2006.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"1551_CR102","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1523\/JNEUROSCI.23-07-03028.2003","volume":"23","author":"M Sch\u00e4fers","year":"2003","unstructured":"Sch\u00e4fers M, Lee DH, Brors D, Yaksh TL, Sorkin LS. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J Neurosci Off J Soc Neurosci. 2003;23:3028\u201338. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-07-03028.2003.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"1551_CR103","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/124942","volume":"2015","author":"M Leo","year":"2015","unstructured":"Leo M, Argalski S, Sch\u00e4fers M, Hagenacker T. Modulation of voltage-gated sodium channels by activation of tumor necrosis factor receptor\u20101 and receptor\u20102 in small DRG neurons of rats. Mediators Inflamm. 2015;2015:124942. https:\/\/doi.org\/10.1155\/2015\/124942.","journal-title":"Mediators Inflamm"},{"key":"1551_CR104","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1007\/s12035-015-9322-z","volume":"53","author":"C-Y Yao","year":"2016","unstructured":"Yao C-Y, Weng Z-L, Zhang J-C, Feng T, Lin Y, Yao S. Interleukin-17A Acts to Maintain Neuropathic Pain Through Activation of CaMKII\/CREB Signaling in Spinal Neurons. Mol Neurobiol. 2016;53:3914\u201326. https:\/\/doi.org\/10.1007\/s12035-015-9322-z.","journal-title":"Mol Neurobiol"},{"key":"1551_CR105","doi-asserted-by":"publisher","first-page":"578068","DOI":"10.1016\/j.jneuroim.2023.578068","volume":"377","author":"J-L Sun","year":"2023","unstructured":"Sun J-L, Dai W-J, Shen X-Y, L\u00fc N, Zhang Y-Q. Interleukin-17 is involved in neuropathic pain and spinal synapse plasticity on mice. J Neuroimmunol. 2023;377:578068. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578068.","journal-title":"J Neuroimmunol"},{"key":"1551_CR106","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","volume":"23","author":"KHG Mills","year":"2023","unstructured":"Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023;23:38\u201354. https:\/\/doi.org\/10.1038\/s41577-022-00746-9.","journal-title":"Nat Rev Immunol"},{"key":"1551_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999407","volume":"13","author":"X Jiang","year":"2022","unstructured":"Jiang X, Zhou R, Zhang Y, Zhu T, Li Q, Zhang W. Interleukin-17 as a potential therapeutic target for chronic pain. Front Immunol. 2022;13:999407. https:\/\/doi.org\/10.3389\/fimmu.2022.999407.","journal-title":"Front Immunol"},{"key":"1551_CR108","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11916-024-01227-5","volume":"28","author":"S Kataria","year":"2024","unstructured":"Kataria S, Patel U, Yabut K, Patel J, Patel R, Patel S, et al. Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options. Curr Pain Headache Rep. 2024;28:321\u201333. https:\/\/doi.org\/10.1007\/s11916-024-01227-5.","journal-title":"Curr Pain Headache Rep"},{"key":"1551_CR109","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/medicina61061063","volume":"61","author":"AD Kaye","year":"2025","unstructured":"Kaye AD, Armistead G, Amedio LS, Manthei ME, Ahmadzadeh S, Bernhardt B, et al. Evolving Treatment Strategies for Neuropathic Pain: A Narrative Review. Med (Mex). 2025;61:1063. https:\/\/doi.org\/10.3390\/medicina61061063.","journal-title":"Med (Mex)"},{"key":"1551_CR110","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177:1401\u20139. https:\/\/doi.org\/10.1111\/bjd.15748.","journal-title":"Br J Dermatol"},{"key":"1551_CR111","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40257-026-01011-8","volume":"27","author":"A Martorell","year":"2026","unstructured":"Martorell A, Ingram JR, Sayed CJ, Bechara FG, Porter ML, Tzellos T, et al. Defining moderate disease and progression in hidradenitis suppurativa: an expert framework to unlock the window of opportunity for prompt treatment. Am J Clin Dermatol. 2026;27:217\u201326. https:\/\/doi.org\/10.1007\/s40257-026-01011-8.","journal-title":"Am J Clin Dermatol"},{"key":"1551_CR112","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70264","author":"G Nikolakis","year":"2026","unstructured":"Nikolakis G, Alpsoy E, Anzengruber F, Augustin M, Bechara FG, Becherel P-A, et al. Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa. J Eur Acad Dermatol Venereol JEADV. 2026. https:\/\/doi.org\/10.1111\/jdv.70264.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1551_CR113","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000453355","volume":"232","author":"A Kouris","year":"2016","unstructured":"Kouris A, Platsidaki E, Christodoulou C, Efstathiou V, Dessinioti C, Tzanetakou V, et al. Quality of Life and Psychosocial Implications in Patients with Hidradenitis Suppurativa. Dermatology. 2016;232:687\u201391. https:\/\/doi.org\/10.1159\/000453355.","journal-title":"Dermatology"},{"key":"1551_CR114","unstructured":"Centene Corporation. Clinical Policy: Adalimumab (Humira), Adalimumab-atto (Amjevita) 2016."},{"key":"1551_CR115","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00403-024-03371-9","volume":"316","author":"N Arora","year":"2024","unstructured":"Arora N, Skaggs E, Bicknell L. Limitations in medicaid coverage of biologics for the treatment of hidradenitis suppurativa. Arch Dermatol Res. 2024;316:619. https:\/\/doi.org\/10.1007\/s00403-024-03371-9.","journal-title":"Arch Dermatol Res"},{"key":"1551_CR116","unstructured":"Louisiana Medicaid. Louisiana Uniform Prescription Drug Prior Authorization Form: Adalimumab-bwwd (Hadlima) 2023."},{"issue":"1","key":"1551_CR117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11916-025-01384-1","volume":"29","author":"MLG Leoni","year":"2025","unstructured":"Leoni MLG, Mercieri M, Viswanath O, Cascella M, Rekatsina M, Pasqualucci A, Caruso A, Varrassi G. Neuropathic Pain: A Comprehensive Bibliometric Analysis of Research Trends, Contributions, and Future Directions. Curr Pain Headache Rep. 2025;29(1):73. https:\/\/doi.org\/10.1007\/s11916-025-01384-1. PMID: 40183995; PMCID: PMC11971142.","journal-title":"Curr Pain Headache Rep"},{"issue":"8","key":"1551_CR118","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/13543784.2024.2376570","volume":"33","author":"WC Upshaw","year":"2024","unstructured":"Upshaw WC, Richey JM, Ravi G, Chen A, Ahmadzadeh S, Shekoohi S, et al. An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions. Expert Opin Investig Drugs. 2024;33(8):829\u201337. https:\/\/doi.org\/10.1080\/13543784.2024.2376570.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"1551_CR119","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/14728214.2024.2323193","volume":"29","author":"WC Upshaw","year":"2024","unstructured":"Upshaw WC, Soileau LG, Storey NR, Perkinson KA, Luther PM, Spillers NJ, Robinson CL, Miller BC, Ahmadzadeh S, Viswanath O, Shekoohi S, Kaye AD. An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia. Expert Opin Emerg Drugs. 2024;29(2):103\u201312. Epub 2024 Feb 29. PMID: 38410863.","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-026-01551-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:26:03Z","timestamp":1788150363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-026-01551-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1007\/s11916-026-01551-y","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is based on previous studies and contains no new studies with human participants or animals performed by any authors.","order":1,"name":"Ethics","label":"Human Participants or Animals","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. A.D.K. is the editor in cheif of CPHRs.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}